Rienso® (ferumoxitol) ofrece una nueva opción de tratamiento para pacientes renales (y 2)

        
        1) Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron
          deficiency anemia in CKD. J Am Soc Nephrol 2008; 19: 1599-1605.
        2) AMAG Pharmaceuticals. Datos archivados.
        3) Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron
          replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 386-393.
        4) Schiller B, Bhat P, Sharma A, et al. Safety of Feraheme(R) (Ferumoxytol) in
          hemodialysis patients at 3 dialysis chains over a 1-year period. J Am Soc Nephrol
          2011; 22: 477A-478A. Abstr FR-PO1573.
        5) Sharma A, Bhat P, Schiller B, et al. Efficacy of Feraheme(R) (Ferumoxytol)
          administration on target hemoglobin levels and other iron parameters across 3 dialysis
          chains. J Am Soc Nephrol 2011; 22: 485A. Abstr FR-PO1603.
        6) Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge.
          Lancet 2005; 365: 331-340.
        7) Qunibi WY. The efficacy and safety of current intravenous iron preparations
          for the management of iron-deficiency anaemia: a review. Arzneimittelforschung 2010;
          60: 399-412.
        8) Schmidt RJ, Dalton CL. Treating anemia of chronic kidney disease in the
          primary care setting: cardiovascular outcomes and management recommendations.
          Osteopath Med Prim Care 2007; 1: 14.
        9) O'Mara NB. Anemia in patients with chronic kidney disease. Diabetes Spectrum
          2008; 21: 12-19.
          10) National Kidney Foundation. KDOQI clinical practice guidelines and clinical
          practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;
          47:S11-15.

CONTACTO: Para consultas de medios: Danny Stepto, Takeda: +41-79-609-9452,danny.stepto@takeda.com.